PI3KCA is mutated in approximately 40% of patients with HR-positive, HER2-negative advanced breast cancer, and is associated with treatment resistance and poor outcomes.
Neoadjuvant treatment with GEMCAP, FOLFIRINOX, or capecitabine plus radiotherapy prolonged OS compared with immediate surgery in patients with pancreatic cancer.
CAR-T therapy containing 2 anti-BCMA single-domain antibodies resulted in high response and PFS rates, according to phase 1b results.
Antibody-drug conjugate trastuzumab deruxtecan demonstrated promising efficacy against relapsed, metastatic, HER2+ CRC according to results from a phase 2 trial.
Adjuvant treatment of GIST with imatinib for 36 months prolonged OS and RFS compared with 12 months of imatinib, according to data from nearly 10 years of follow-up.
Anti-BCMA CAR T-cell therapy idecabtagene vicleucel demonstrated promising efficacy among patients with heavily pretreated and refractory MM.
The Society of Gynecologic Oncology published recommendations to guide clinicians through shared decision making with patients about anticancer treatment.
Molecular subtypes, as indicated by the ProMisE classifier, of endometrial clear cell carcinoma are associated with different prognoses.
This fact sheet describes how artificial intelligence is currently being used in oncology.
First-line treatment of early-stage, unfavorable classic Hodgkin lymphoma with nivolumab plus doxorubicin, vinblastine, and dacarbazine resulted in high response rates and PFS in a phase 2 study.
